{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:26:28Z","timestamp":1788276388469,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007313","name":"MD Anderson Cancer Center","doi-asserted-by":"crossref","award":["Leukemia SPORE CA100632"],"award-info":[{"award-number":["Leukemia SPORE CA100632"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH\/NCI","award":["Cancer Center Support Grant P30 CA016672."],"award-info":[{"award-number":["Cancer Center Support Grant P30 CA016672."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01825-3","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:35:01Z","timestamp":1782570901000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study"],"prefix":"10.1186","volume":"19","author":[{"given":"Nicholas J.","family":"Short","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Bataller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Montalban-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Hachem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghayas C.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly S.","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maro","family":"Ohanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Karrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan","family":"Bachireddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunsoo","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"1825_CR1","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/ajh.26984","volume":"98","author":"G Garcia-Manero","year":"2023","unstructured":"Garcia-Manero G. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:1307\u201325.","journal-title":"Am J Hematol"},{"key":"1825_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136\u201352.","journal-title":"N Engl J Med"},{"key":"1825_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41408-024-01143-2","volume":"14","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, et al. Current status and research directions in acute myeloid leukemia. Blood Cancer J. 2024;14:163.","journal-title":"Blood Cancer J"},{"key":"1825_CR4","doi-asserted-by":"crossref","unstructured":"Cloos J et al. 2025 Update on MRD in Acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party. Blood. 2026;147(11):1147\u201367.","DOI":"10.1182\/blood.2025031480"},{"key":"1825_CR5","first-page":"3543","volume":"109","author":"A Bataller","year":"2024","unstructured":"Bataller A, et al. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica. 2024;109:3543\u201356.","journal-title":"Haematologica"},{"key":"1825_CR6","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ, et al. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020;6:1890\u20139.","journal-title":"JAMA Oncol"},{"key":"1825_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/bjh.16857","volume":"191","author":"A Bataller","year":"2020","unstructured":"Bataller A, et al. Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. Br J Haematol. 2020;191:52\u201361.","journal-title":"Br J Haematol"},{"key":"1825_CR8","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1182\/bloodadvances.2022009391","volume":"7","author":"A Bazinet","year":"2023","unstructured":"Bazinet A, et al. Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. Blood Adv. 2023;7:3284\u201396.","journal-title":"Blood Adv"},{"key":"1825_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ajh.27482","volume":"100","author":"NJ Short","year":"2025","unstructured":"Short NJ, Dillon R. Measurable residual disease monitoring in AML: Prospects for therapeutic decision-making and new drug development. Am J Hematol. 2025;100:5\u201315.","journal-title":"Am J Hematol"},{"key":"1825_CR10","doi-asserted-by":"publisher","first-page":"E408","DOI":"10.1002\/ajh.26698","volume":"97","author":"NJ Short","year":"2022","unstructured":"Short NJ, et al. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission. Am J Hematol. 2022;97:E408\u201311.","journal-title":"Am J Hematol"},{"key":"1825_CR11","doi-asserted-by":"publisher","first-page":"106555","DOI":"10.1016\/j.leukres.2021.106555","volume":"104","author":"JS Garcia","year":"2021","unstructured":"Garcia JS, et al. A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. Leuk Res. 2021;104:106555\u2013106555.","journal-title":"Leuk Res"},{"key":"1825_CR12","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","volume":"29","author":"T Pr\u00e9bet","year":"2011","unstructured":"Pr\u00e9bet T, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29:3322\u20137.","journal-title":"J Clin Oncol"},{"key":"1825_CR13","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1182\/blood-2017-10-811729","volume":"131","author":"AM Zeidan","year":"2018","unstructured":"Zeidan AM, et al. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood. 2018;131:818\u201321.","journal-title":"Blood"},{"key":"1825_CR14","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1002\/cncr.25247","volume":"116","author":"E Jabbour","year":"2010","unstructured":"Jabbour E, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010;116:3830\u20134.","journal-title":"Cancer"},{"key":"1825_CR15","first-page":"1261","volume":"86","author":"L Mu\u00f1oz","year":"2001","unstructured":"Mu\u00f1oz L, et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica. 2001;86:1261\u20139.","journal-title":"Haematologica"},{"key":"1825_CR16","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3390\/cancers11091358","volume":"11","author":"U Testa","year":"2019","unstructured":"Testa U, Pelosi E, Castelli G. CD123 as a Therapeutic target in the treatment of hematological malignancies. Cancers. 2019;11:1358.","journal-title":"Cancers"},{"key":"1825_CR17","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","volume":"380","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380:1628\u201337.","journal-title":"N Engl J Med"},{"key":"1825_CR18","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1182\/blood.V124.21.2316.2316","volume":"124","author":"SY Chu","year":"2014","unstructured":"Chu SY, et al. Immunotherapy with Long-Lived Anti-CD123 \u00d7 Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD123\u2009+\u2009Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia. Blood. 2014;124:2316\u20132316.","journal-title":"Blood"},{"key":"1825_CR19","doi-asserted-by":"publisher","first-page":"6492","DOI":"10.1182\/bloodadvances.2023010956","volume":"7","author":"F Ravandi","year":"2023","unstructured":"Ravandi F, et al. Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed\/refractory acute myeloid leukemia. Blood Adv. 2023;7:6492\u2013505.","journal-title":"Blood Adv"},{"key":"1825_CR20","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"1825_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419\u201325.","journal-title":"Blood"},{"key":"1825_CR22","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/cyto.b.22140","volume":"104","author":"SA Wang","year":"2023","unstructured":"Wang SA, et al. Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal\/measurable residual disease detection. Cytometry Part B: Clin Cytometry. 2023;104:356\u201366.","journal-title":"Cytometry Part B: Clin Cytometry"},{"key":"1825_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5858\/arpa.2025-0053-OA","volume":"150","author":"SA Wang","year":"2025","unstructured":"Wang SA, et al. Technical and clinical validity of assessing measurable residual disease by multicolor flow cytometry in an unselected acute myeloid leukemia patient cohort. Arch Pathol Lab Med. 2025;150:72\u201380.","journal-title":"Arch Pathol Lab Med"},{"key":"1825_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343\u20136.","journal-title":"Control Clin Trials"},{"key":"1825_CR25","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"1825_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1:1\u201314.","journal-title":"NEJM Evid"},{"key":"1825_CR27","doi-asserted-by":"crossref","unstructured":"Elena C et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128:1408\u201318.","DOI":"10.1182\/blood-2016-05-714030"},{"key":"1825_CR28","first-page":"2047","volume":"141","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, et al. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes. Blood. 2023;141:2047\u201361.","journal-title":"Blood"},{"key":"1825_CR29","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1182\/blood-2025-2075","volume":"146","author":"K Chien","year":"2025","unstructured":"Chien K, et al. Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes. Blood. 2025;146:2075\u20132075.","journal-title":"Blood"},{"key":"1825_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2025.107692","volume":"153","author":"JS Braish","year":"2025","unstructured":"Braish JS, et al. Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome. Leuk Res. 2025;153:107692.","journal-title":"Leuk Res"},{"key":"1825_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01319-y","volume":"15","author":"S Lee","year":"2022","unstructured":"Lee S, et al. Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents. J Hematol Oncol. 2022;15:103.","journal-title":"J Hematol Oncol"},{"key":"1825_CR32","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3324\/haematol.2018.207118","volume":"104","author":"S Marie","year":"2019","unstructured":"Marie S, et al. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Haematologica. 2019;104:1565\u201371.","journal-title":"Haematologica"},{"key":"1825_CR33","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","volume":"12","author":"NG Daver","year":"2022","unstructured":"Daver NG, et al. TP53-Mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions. Cancer Discov. 2022;12:2516\u201329.","journal-title":"Cancer Discov"},{"key":"1825_CR34","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","volume":"4","author":"J Vadakekolathu","year":"2020","unstructured":"Vadakekolathu J, et al. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. Blood Adv. 2020;4:5011\u201324.","journal-title":"Blood Adv"},{"key":"1825_CR35","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1182\/blood.2024027500","volume":"145","author":"R Bassan","year":"2025","unstructured":"Bassan R, et al. Up-front blinatumomab improves MRD clearance and outcome in adult Ph\u2013 B-lineage ALL: the GIMEMA LAL2317 phase 2 study. Blood. 2025;145:2447\u201359.","journal-title":"Blood"},{"key":"1825_CR36","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522\u201331.","journal-title":"Blood"},{"key":"1825_CR37","doi-asserted-by":"crossref","unstructured":"Liu M et al. Immunosuppressive cells in acute myeloid leukemia: mechanisms and therapeutic target. Front Immunol. 2025;16:1627161.","DOI":"10.3389\/fimmu.2025.1627161"},{"key":"1825_CR38","doi-asserted-by":"publisher","first-page":"eaaz0463","DOI":"10.1126\/scitranslmed.aaz0463","volume":"12","author":"J Vadakekolathu","year":"2020","unstructured":"Vadakekolathu J, et al. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Sci Transl Med. 2020;12:eaaz0463.","journal-title":"Sci Transl Med"},{"key":"1825_CR39","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","volume":"25","author":"NG Daver","year":"2024","unstructured":"Daver NG, et al. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study. Lancet Oncol. 2024;25:388\u201399.","journal-title":"Lancet Oncol"},{"key":"1825_CR40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815105","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. New England Journal of Medicine. 2019;380:1628-1637. https:\/\/doi.org\/10.1056\/NEJMoa1815105","journal-title":"New England Journal of Medicine"},{"key":"1825_CR41","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1182\/blood-2014-04-566737","volume":"124","author":"AE Frankel","year":"2014","unstructured":"Frankel AE, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124:385\u201392.","journal-title":"Blood"},{"key":"1825_CR42","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1182\/blood.2020007732","volume":"137","author":"GL Uy","year":"2021","unstructured":"Uy GL, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021;137:751\u201362.","journal-title":"Blood"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01825-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01825-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01825-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:07:02Z","timestamp":1788275222000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01825-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1825"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01825-3","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This clinical trial was conducted at a single academic medical center (The University of Texas MD Anderson Cancer Center). The clinical trial was approved by the Institutional Review Board and was conducted in accordance with the Declaration of Helsinki. All participants signed informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.J.S. declares grants from Takeda Oncology, Astellas Pharma Inc., Xencor, Stemline Therapeutics and Nexcure, consultancy from Pfizer Inc., GSK, NKARTA and Sanofi, honoraria from Adaptive Biotechologies, Novartis, Amgen, Takeda, Pfizer Inc., Astellas Pharma Inc., Sanofi and BeiGene, consulting fees from Amgen, Pfizer Inc., GSK, Adaptive Biotechnologies, Autolus, Sanofi, Syndax, Merck, Ascentage, Novartis, AB Science, research funding from Takeda Oncology, Astellas Pharma Inc., Xencor, GSK, NextCure, Ascentage, Novartis, Hemogenyx, Vironexis, and Remedy Plan, honoraria from Adaptive Biotechnologies, Novartis, Amgen, Takeda Oncology, Pfizer Inc., Astellas Pharma Inc., Sanofi, Merck, AstraZeneca A.B. declares no conflict of interest. C.D.D declares Honoraria from AbbVie, GlaxoSmithKline, Servier, Genentech\/AbbVie, Astellas Pharma, Bristol Myers Squibb Foundation, Schrodinger, Daiichi Sankyo\/Astra Zeneca, Ellipses Pharma, consultancy or Advisory Role for AbbVie, AstraZeneca, Genmab, Molecular Partners, Servier, Schrodinger, Rigel, Ryvu Therapeutics, research funding from AbbVie, Cleave Therapeutics, Foghorn Therapeutics, Immune-Onc Therapeutics, Jazz Pharmaceuticals, Servier, Loxo\/Lilly, Astex Pharmaceuticals, Bristol Myers Squibb\/Celgene, BeiGene and Remix Therapeutics. G.M-B. declares research support from Takeda, Rigel and IFN Therapeutics. S.W. declares no conflict of interest. W.W. declares no conflict of interest. A.M. declares research funding from Chimeric Therapeutics, Cero Therapeutics, Sanofi Aventis, BMS, Astex Pharmaceuticals, IGM Bio, Takeda Oncology, Biosight, Electra Therapeutics, Imcheck Therapeutics, Hibercell, Arce Therapeutics, Lin Biosciences and serves as an advisor\/consultant to Caribou Bio, Ingenium Therapeutics, Orum Therapeutics, Electra Therapeutics, Galecto, Ferring, Nextech, Vitruviae, Puretech. D.N. declares no conflict of interest. T.M.B. declares no conflict of interest. G.C.I. declares consultancy from Novartis, Kura Oncology, Nuprobe, and research funding from Celgene, Kura Oncology, Syndax, Merck, Cullinan, and Novartis. K.S.C. declares research funding from Amgen and consultancy from AbbVie. M.O. declares no conflict of interest. T.M.K. declares grants from BMS, Abbvie, Amgen, Ascentage Pharma Group, Astellas Pharma, DrenBio, Astex, AstraZeneca, BMS, Celgene, Incyte, Cellenkos, Cyclacel, Delta-Fly pharma, Genentech, Genfleet, Glycomimetics, Iterion, Janssen, Jazz Pharmaceuticals, Pfizer, Pulmotect, Regeneron, SELLAS, consultancy from AbbVie, Agios, Daiichi Sankyo, Genentech, Genzyme, Jazz Pharmaceuticals, Liberum, Novartis, Pfizer, PinotBio, Pukmotect, Sanofi-Aventis, Servier, honoraria from AbbVie, Agios, Daiichi Sankyo, DAVA Oncology, Delta-Fly, DrenBio, Genentech, Genfleet, Genzyme, Jazz Pharmaceuticals, Liberum, Novartis, Pfizer, Rigel, Sanofi-Aventis, SELLAS and Servier. S.L. declares Research support from Amgen and Astellas, consulting from AbbVie, Arima, Blueprint Medicine, BMS, Caris Diagnostics, Daiichi-Sankyo, Immunogen, Kura Oncology, Recordati, Servier, Stemline, Syndax, Tempus AI. O.K. declares no conflict of interest. P.B. declares no conflict of interest. H.H. declares no conflict of interest. X.H. declares no conflict of interest. G.G-M declares research funding from Astex Pharmaceuticals, Novartis, Abbvie, BMS, Genentech, Aprea Therapeutics, Curis, Gilead Sciences, consultancy from Astex Pharmaceuticals, Acceleron Pharma, BMS, and honoraria from Astex Pharmaceuticals, Acceleron Pharma, Abbvie, Novartis, Gilead Sciences, Curis, Genentech, BMS. All other authors declare no conflicts of interests. F.R. declares honoraria from Amgen, Pfizer, Astellas Pharma, Celgene, Agios, AbbVie\/Genentech, AstraZeneca, Bristol Myers Squibb, Takeda, Jazz Pharmaceuticals, Novartis, Syros Pharmaceuticals, Taiho Pharmaceutical, Syndax, consultancy from Amgen, Astellas Pharma, Celgene, Jazz Pharmaceuticals, Agios, AbbVie\/Genentech, Bristol Myers Squibb, AstraZeneca, Taiho Oncology, Syros Pharmaceuticals, Certara Inc., research funding from Bristol Myers Squibb, Amgen, Macrogenics, Xencor, Selvita, Cellerant, Astex Pharmaceuticals, Taiho Oncology, Syros Pharmaceuticals, Prelude Therapeutics, Biomea Fusion, Astellas Pharma.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"63"}}